Business Context and Reporting Period
Company: Utah Medical Products, Inc. (UTMD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2008
Business Overview: UTMD manufactures and markets single-use specialty medical devices, primarily in obstetrics, gynecology, neonatal, and blood pressure monitoring. The company operates manufacturing facilities in the U.S. and Ireland.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended 9/30/08 | 9 Months Ended 9/30/08 | 9 Months Ended 9/30/07 |
|---|---|---|---|
| Sales, Net | $7,181 | $21,185 | $21,426 |
| Gross Profit | $3,937 | $11,608 | $11,915 |
| Operating Income | $2,940 | $8,178 | $8,128 |
| Net Income | $1,820 | $5,628 | $5,950 |
| Diluted EPS | $0.47 | $1.44 | $1.49 |
| Cash & Investments | $22,395 (as of 9/30/08) | ||
| Total Debt | $2,594 (Current: $298; Long-term: $2,296) | ||
| Working Capital | $27,061 (Current Assets $30,205 - Current Liab $3,144) |
Margins (9 Months 2008 vs 2007):
- Gross Profit Margin: 54.8% (vs 55.6%)
- Operating Profit Margin: 38.6% (vs 37.9%)
- Net Income Margin: 26.6% (vs 27.8%)
Material Changes vs. Prior Period
- Revenue: Sales were flat for the quarter (+1%) and slightly down for the nine-month period (-1%). Domestic direct sales declined 1% in the quarter, while domestic OEM sales rose 24%. International sales increased 3% in the quarter and 4% for the nine months.
- Profitability: Net income decreased 10% in the quarter and 5% for the nine months compared to the prior year. The decline was primarily driven by a significant non-operating expense in Q3 2008.
- Non-Operating Items: Q3 2008 recorded a non-operating expense of $213,000, compared to income of $365,000 in Q3 2007. This was due to a $428,000 realized capital loss from writing off the investment in Washington Mutual (WM) common stock, partially offset by a $250,000 reduction in the management bonus reserve.
- Costs: Gross profit margins compressed slightly due to higher raw material costs (plastics), transportation costs, and labor. Operating expenses decreased due to the bonus reserve adjustment and lower sales expenses.
- Liquidity: Cash decreased from $1,251,000 to $883,000 during the nine months, despite strong operating cash flow of $5,920,000. Cash outflows were driven by $2,625,000 in dividends, $1,908,000 in share repurchases, and $1,502,000 in debt repayments.
Guidance, Outlook, and Risks
Outlook: Management explicitly stated it is not able to provide a projection for the remainder of 2008. This is due to the credit market crisis, the dramatic fluctuation of the Euro against the U.S. Dollar, and concerns regarding a potential recession affecting customer order patterns.
Capital Allocation: The company plans to use excess cash for selective acquisitions, continued share repurchases when undervalued, and capital expenditures (expected to be under $200,000 for the remainder of 2008).
Risks and Contingencies:
- Investment Loss: The company wrote off its investment in Washington Mutual (WM) following WM's liquidity failure.
- Foreign Exchange: Operations in Ireland are denominated in Euros. The company does not use hedging transactions, exposing it to currency fluctuations.
- Market Competition: Loss of market share in obstetrics products due to competitor price reductions and administrative restrictions on physician choice.
- Regulatory: Delays in regulatory approvals for new products and changes in reimbursement policies.
Investor Verification Checklist
- Investment Portfolio: Verify the remaining composition and valuation of the $21.5 million investment portfolio (Fidelity Cash Reserves, Citigroup, and remaining Washington Mutual holdings if any).
- Debt Structure: Confirm the repayment schedule and interest terms of the Ireland subsidiary's note payable (approx. €1.8 million remaining).
- Share Repurchases: Review the ongoing open market repurchase program; 20,220 shares were repurchased in Q3 2008 at an average price of $27.63.
- Product Mix: Assess the sustainability of the 24% growth in domestic OEM sales versus the 14% decline in domestic obstetrics sales.
- Currency Exposure: Monitor the impact of the Euro/USD exchange rate on the valuation of Irish assets and future revenue translation.